ALEX, a global, randomized, phase III trial evaluated alectinib versus crizotinib in patients with advanced ALK-positive non-small cell lung cancer (NSCLC). This final analysis provides mature overall survival (OS), duration of response (DOR) and long-term safety data.
Alectinib versus crizotinib in previously untreated ALK-positive advanced non-small cell lung cancer: final overall survival analysis of the phase III ALEX study☆
Annals of Oncology | | S. Peters, R. Camidge, R. Dziadziuszko, S. Gadgeel, A.T. Shaw, D.-W. Kim, M. Pérol, D.R. Rosell, P. Cheema, D. Wan-Teck Lim, J.J. Lin, N. Pavlakis, J.S. Ahn, L. Zhang, V. Henschel, A.A. Higgerson, V. McNally, I. Rooney, A. Scalori, V. Smoljanovic, T. Mok
Topics: lung-cancer, blood-cancer, clinical-trials, research